Stock comparison
IDEXX Laboratories
Rigel Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | RIGL | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 47D | IDXX |
| Benjamin Graham | 80A | 34F | IDXX |
| Philip Fisher |
Side-by-side metrics
| Metric | IDXX | RIGL |
|---|---|---|
| Market cap | $44.12B | $536.75M |
| P/E (TTM) | 39.0x | 1.4x |
| EV/EBIT | 31.6x | 4.3x |
| ROIC (TTM) | 40.66% | 27.96% |
| Gross margin | 62.05% | 93.39% |
| Net margin | 24.63% | 121.51% |
| Revenue CAGR 5y | 7.56% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $536.75M+99%
- ROIC (TTM)40.66%vs 27.96%+31%
RIGL leads on
- P/E (TTM)1.4xvs 39.0x+96%
More like RIGL
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.